The increasing prevalence of cardiovascular disease among individuals living with HIV is prompting renewed research into the complex interplay between the virus, immune response and heart health, according to a review published in September 2025 in Frontiers in Cardiovascular Medicine.
While advancements in antiretroviral therapy have transformed HIV from a rapidly fatal illness into a manageable chronic condition, people living with HIV continue to experience a significantly higher incidence of cardiovascular complications, and often at an earlier age than the general population. This trend, first observed early in the AIDS epidemic even before the identification of HIV, persists despite viral suppression achieved through modern treatments.
Researchers are now focusing on the subtle effects of HIV on the cardiovascular system, moving beyond the previously understood link between profound immunodeficiency and HIV-associated cardiomyopathy. The pathogenesis of these cardiovascular issues is proving complex, involving both direct viral impacts and indirect consequences of chronic inflammation. A recent review in the Cleveland Clinic Journal of Medicine highlights that this increased risk is attributable to chronic inflammation and other biochemical factors, alongside overlapping social determinants of health.
Cardiac abnormalities were identified in AIDS patients as early as the 1980s, preceding a full understanding of the virus itself. Initial cases were largely characterized by cardiomyopathy linked to severe immune suppression. However, as antiretroviral therapies became more effective, the nature of HIV-associated cardiovascular disease evolved. Current research, as detailed in a PubMed publication, emphasizes the need for deeper understanding of the immunological factors at play.
The prevalence of cardiac involvement in individuals with AIDS has been reported to range from 28% to 73%, according to research published in JAMA Internal Medicine. The longer survival rates now seen in HIV patients, thanks to improved treatment, mean that a wider range of cardiovascular manifestations are becoming apparent.
The review published in Frontiers in Cardiovascular Medicine, authored by a team of researchers from institutions in the United States and Nigeria, examines the molecular mechanisms, clinical presentations, diagnostic approaches, and treatment strategies related to HIV-associated cardiomyopathy. The authors emphasize the particular relevance of their findings to populations originating from regions with high HIV prevalence, such as sub-Saharan Africa.
Researchers are utilizing advanced cardiac imaging modalities and immunological studies to unravel the intricacies of HIV-associated cardiovascular disease. The Cleveland Clinic Journal of Medicine article stresses the importance of careful cardiovascular risk assessment and management in this patient population, given the earlier onset of coronary artery disease compared to the general population.
Despite progress in understanding the link between HIV and heart disease, significant evidence gaps remain. The Frontiers in Cardiovascular Medicine review calls for further research to better understand the complex interactions between HIV and the cardiovascular system. No immediate changes in treatment guidelines have been announced, and further study is planned.
